Low temperature calorimetry of 3-fluoro-5-(3-pyridinyloxy) benzenamine and N-[3-fluoro-5-(3-pyridinyloxy)phenyl]-N’-3-pyridinyl urea

Abstract

The investigation on thermodynamic properties of drug intermediates plays a crucial role in the design and synthesis of new drugs as well as understanding their biological activities in vivo. In this work, the thermodynamic properties of two drug intermediates of 3-fluoro-5-(3-pyridinyloxy) benzenamine and N-[3-fluoro-5-(3-pyridinyloxy)phenyl]-N’-3-pyridinyl urea were studied by means of low temperature calorimety performed in a Physical Property Measurement System calorimeter. The heat capacities of these two compounds were measured over the temperature region from (1.9 to 300) K, and the corresponding thermodynamic functions were consequently calculated on the basis of the heat capacity curve fitting. Additionally, a group additivity method were employed for estimating the heat capacity values of these two compounds at 298.15 K, which are in good agreement with the values measured in this work.

Keywords

• 3-fluoro-5-(3-pyridinyloxy) benzenamine,N-,3-fluoro-5-(3-pyridinyloxy)phenyl,-N’-3-pyridinyl urea,Low temperature calorimetry,Heat capacity

References

1. 1. Ghodsi R, Zarghi A, Daraei B, et al. Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2010; 18: 1029-1033.
2. 2. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ. GPR120 agonism as a countermeasure against metabolic deseases. Drug Discovery Today. 2014; 19: 670-679.
3. 3. Hara T, Kimura I, Inoue D, et al. Free fatty acid receptors and their role in regulation of energy metabolism. Rev Physiol Biochem Pharmacol. 2013; 164: 77-116.
4. 4. Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Failure Rev. 2009; 14: 289-298.
5. 5. Offermanns S. Free fatty acid (FFA) and hydroxyl carboxylic acid (HCA) receptors. Annu Rev Pharmacol Toxicol. 2014; 54: 407-434.
6. 6. Azevedo CMG, Watterson KR, Wargent ET, et al. Non-acidic free fatty acid receptor 4 agonists with antidiabetic activity. J Med Chem. 2016; 59: 8868-8878.
7. 7. Morgan BP, Muci A, Lu PP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett. 2010; 1: 472-477.
8. 8. Schwaller MA, Dodin G, Aubard J. Thermodynamics of drug-DNA interactions: entropy-driven intercalation and enthalpy-driven outside binding in the ellipticine series. Biopolymers. 1991; 31: 519-527.

9. 9. Sangster J. Phase diagrams and thermodynamic properties of binary systems of drugs. J Phys Chem Ref Data. 1999; 28(4): 889-930.
10. 10. Du J, Wang X, Tan Z, Zou G. Thermodynamic investigation on para-alkyl chain-substituted phenylbicyclohexyl-type liquid crystals with difluorooxymethylene bridge. J Therm Anal Calorim. 2016; doi 10.1007/s10973-016-5852-5.